

Activity Report

Life Sciences and Health Technologies
of Greater Montréal

2019

MONTRÉAL
INVIVO 



Click for more information!

This document contains buttons and logos providing access to additional information.



Consult a web link



View a video

Table of Contents

3 Interviews with the Chief Executive Officer and the Chairman of the Board of Directors

7 Our DNA

9 Industry snapshot

10 The work of the Strategic Committees

11 Strategic Committee 01 — Growth of Companies

16 Strategic Committee 02 — Skills and Talent Development

21 Strategic Committee 03 — Integration of Innovations

26 Strategic Committee 04 — Issues Monitoring and Management

29 Strategic Committee 05 — Research and Innovation

34 Strategic Committee 06 — Artificial Intelligence

37 Outreach

40 Mobilization

44 Decision-makers

46 Our allies

48 Our team

50 Stakeholders' presence



Frank
Béraud

INTERVIEW

Chief Executive Officer

How would you describe the year 2019 for Montréal InVivo?

The year we had to work extra hard! We had to deal with unexpected staff departures, which meant we had to take the time to find replacements and put pressure on our small team to work even harder to deliver projects while maintaining the same level of quality in the work they were doing. I believe that the impact of these departures was not felt too much outside the organization. As a hockey coach would say, the other players took on more responsibility to fill in the gaps. I would like to thank the team for all the effort they made for the good of our life sciences ecosystem. And all the while preparing for a move that took place at the beginning of 2020. Good job!



Name one or two major achievements for Montréal InVivo of which you are proud.

That's easy! The first edition of EFFERVESCENCE. It had been a long time since the community had wanted a major life sciences event to be held in Montréal so we decided to make it happen! But we didn't do it alone. We brought together 13 partners from the community to co-organize this event, which was a very big success. I am really proud of this collective success. Less visibly, we worked a lot over the last year on critical issues for life sciences such as that of the talent pool for which important announcements will be made in 2020 and the issue of access to health data. Regarding this last issue, I am particularly proud of the brief prepared following the industry consultations. It was met with an extremely warm reception by the firms and officials concerned.



[View the brief](#)

What will be the major issues for Montréal InVivo in 2020?

2020 will be a year of major changes for Montréal InVivo. New address, new visual identity and new members of the team. It is also a year in which we are going to solidify certain strategic committees undertaken in 2019, such as that dedicated to medical cannabis, which is developing nicely. We successfully grouped together some of the most significant players from this niche and there is a strong willingness to work together to better structure this industry.

What motivates you for the coming year?

After having successfully integrated the changes from the beginning of the year, it is clearly Montréal InVivo's strategic planning for the new 2021-2023 cycle that drives me the most. I see it as a unique opportunity to reflect on what we have done, strengthen our positioning and especially imagine other possibilities to develop the life sciences and health technologies cluster of Greater Montréal even more effectively.



Martin
LeBlanc

INTERVIEW

Chairman of the Board of Directors

Why are you involved on the Board of Directors (the Board) of Montréal InVivo?

My involvement as Chair stems from the importance I attach to Montréal InVivo's mandate and to its role as a catalyst driving the vitality of the life sciences sector. In my opinion, Montréal InVivo is at the heart of several projects that aim to raise and continue to develop the life sciences and health technologies cluster. The Board offers a rather rare opportunity to bring around the same table the leaders of the vital components of the cluster in order to have well-informed opinions from all stakeholders in the sector.



How would you describe year 2019 for the LSHT sector?

It was a good year. We continue to see increased vitality in the life sciences sector and the companies are doing well. Many new companies have been created and several have been successful in terms of financing, developing their technologies and creating jobs. We also observe the emergence of new technologies in our sector, particularly in artificial intelligence as it applies to the health field. I believe that 2019 was a year that kind of reflected the vitality found in several other technology sectors in Montréal, but the life sciences sector was a leader. I also think there is still a lot of work to be done to grow the companies and keep them here.

Name one of Montréal InVivo's priorities for 2020.

Certainly the creation of an innovation area for Montréal's life sciences sector is a priority which we are going to have to monitor closely. The provincial government's strategy is going to result in the creation of innovation areas in 2020 and I truly hope there will be a health-focused innovation area in Montréal. I believe there is a golden opportunity

to position itself in this area and that Montréal InVivo is well placed to serve as a catalyst in bringing together several stakeholders to ensure collaboration and coordination between the different ongoing projects. We are going to have to be able to demonstrate the potential of a single world-class area with a number of impactful projects.

Do you have a message for the stakeholders in the sector?

Check out Montréal InVivo's activities. Take an interest in our activities to derive maximum benefit for yourself. Your commitment will influence the cluster's priorities. They are significant and vital. We cannot be at our best and fulfill our mission without the involvement and interest of the stakeholders in the sector.



Our DNA

Montréal InVivo is the Life sciences and Health technology (LSHT) cluster of Greater Montréal.

We are a non-profit economic development organization that aims to create a business environment conducive to innovation and development of public and private organizations in the LSHT sector.

AREAS OF INTERVENTION



Capitalize

on research and innovation



Promote

the integration of innovation



Support

the growth of companies



Develop

expertise and succession
planning



Ensure

the cluster's outreach

Montréal InVivo's activities are supported by funding from the Ministry of Economy and Innovation (MEI), the Secretariat for the Metropolitan Region of the Ministry of Municipal Affairs and Housing (MAMH), of the Montréal Metropolitan Community (CMM) and Canada Economic Development (CED) for the regions of Quebec and the private and institutional sectors.

Members

All the organizations, institutions and companies active in the LSHT sector of Great Montréal are in fact part of the cluster. Montréal InVivo assumes a federative leadership over all stakeholders working in this sector, whether they are organizations, institutions or companies.

- Research institutions
- Governments
- Funding organizations
- Companies

-
- Pharmaceutical
 - Biotechnology
 - Health technologies/medical devices (MedTech)
 - Research and contract manufacturing (CRO-CMO)
 - Health IT (including artificial intelligence in life sciences)

Industry Snapshot

A favourable political and financial environment, a talent pool, a cutting-edge research infrastructure and a geographic location that opens onto North America and Europe: Montréal offers the best conditions for success for companies in LSHT sector.

Montréal's LSHT ecosystem has developed into a concentration of strong niches of excellence in which scientific and industrial partnerships broaden. The fast emergence of health technologies, artificial intelligence, personalized medicine and genomics also acts as a vehicle for innovation for industries.



[View the entire snapshot](#)

608
ORGANIZATIONS IN
QUEBEC, INCLUDING

220 biopharmaceuticals

30 innovative
pharmaceuticals

342 medical technologies

107 natural health
products

The Greater Montréal Area
accounts for approximately
80% of the LSHT activities
in Quebec.

\$5.8 billion
in revenue

i.e. 1.6% of Quebec GDP



8 higher
education
institutions



6,000 new
graduates

each year



58,000 jobs

(including 32,472 direct jobs)
of which close to 80% are
in the Greater Montréal Area



+ than 40 %
of venture capital
investments

in Canada in the LSHT sector



Strategic Committees' Work

To meet the challenges of the sector, Montréal InVivo has the privilege to be able to rely on the work of six strategic committees, aligned along its areas of activity. The work accomplished in these strategic committees, strategically composed of members that are diversified and representative of the ecosystem, enables needs to be identified, impactful solutions to be co-developed and the required actions to then be implemented.



Growth of Companies

MANDATE

Develop a strategy aimed at enhancing the international performance and competitiveness of the LSHT cluster of Greater Montréal.

Montréal InVivo recognizes that a critical mass of successful companies constitutes a significant strategic driver of the economic development of LSHT in the overall value chain. Companies' growth plays a prominent role in the development of the sector, and this is why Montréal InVivo plans to expand the support it provides to SMEs, in addition to what is already being done, by proposing an array of dedicated services and resources in the coming year. We are initiating and supporting the initiatives intended to enhance the performance and competitiveness of the companies active in the sector:

- Oversight and reflection about the public policies and government programs to assist innovation for companies
- Oversight and proposals for the financing chain of LSHT companies
- Development and implementation of an approach based on support and centralized resources for entrepreneurs and innovative companies in life sciences
- Continuing the activities of the BIOSUCCÈS mentoring network



“The success of our LSHT companies is heavily dependent on their access to financing throughout their life cycle and on their ability to develop their skills and human resources in a context of fierce competition. The Strategic Committee brings together several key players from the community, which have the commitment and the know-how required to identify and activate the most promising leads for creating conditions conducive to the growth and outreach of LSHT companies in Montréal and worldwide.”

CÉDRIC BISSON
Partner
Teralys Capital

Achievements

Better equip companies

In 2019, a map of the support organizations was created with the objective of directing entrepreneurs in their search for organizations that could offer various support services. This diagnostic tool will channel the work of the Strategic Committee in addition to guiding companies in their research. This tool and the list of updated government funding programs are available on Montréal InVivo’s website.

In addition, following discussions and meetings with specialized players, the Strategic Committee prioritized three elements that will enhance the financing offer:

- Analysis of corporate funding and charitable funding for SMEs
- Development of a strategy for financing companies’ later phases (Late-Stage Financing)
- Registering Quebec SMEs on the TSX vs. NASDAQ



Consult the tools



AccélérAction Committees

In order to meet the need expressed of having special access to experienced experts specialized in the LSHT sector, the AccélérAction committees were launched in 2019 in collaboration with the TechStars accelerator. In a context of providing “personalized coaching” to companies, the first committee welcomed two startups in the area of artificial intelligence (AI) applied to LSHT, in need of advice on regulatory strategies. Montréal InVivo brought together five experts that contributed their advice and helped business leaders better understand the regulatory issues. The activity was highly appreciated and should take place again next year.

“Montréal InVivo acted quickly by bringing together experts to validate the important points concerning the commercialization of our product, which is situated at the junction between biotechnologies and AI. Montréal InVivo supported us in the achievement of our objectives by putting in place an advisory committee that enabled us to consolidate the key steps of our regulatory and market access strategy.”

MARINA PAVLOVIC RIVAS
Co-founder and CEO
Eli Health

“In one afternoon session, Montréal InVivo gave us the opportunity to share our company’s vision with the different stakeholders in our field, allowing us to grow as entrepreneurs and refine our pitch thanks to direct, candid feedback.”

LUCA CUCCIA
Co-founder and CEO
Micropredictome



BIOSUCCÈS Mentoring Network

This year, Montréal InVivo focused on developing closer relationships with accelerators from Greater Montréal. Four new mentees are now part of a dyad, for a total of 17 active dyads, and two new mentors were recruited. A review was also initiated on how mentors acted and mobilized to effectively meet the needs of the mentees from BIOSUCCÈS.



Consult BIOSUCCÈS



Entrepreneurial Capsules

Montréal InVivo produced two new promotional videos of success stories to showcase the vitality, road map and quality of the business models of Quebec companies and to raise the profile of the cluster's stakeholders.

The first capsule presents the Imagia, a company that combines expertise in health care and cutting-edge artificial intelligence to accelerate diagnosis, and therefore optimizes recovery from serious illnesses such as cancer. Through its EVIDENS platform, its partners learn from the shared clinical data and discover clinical solutions using AI.

The second capsule presents the company Caprion which, founded in 2000, is a leading specialty clinical research organization laboratory providing state-of-the-art platforms in proteomics and immune monitoring services. It has conducted more than 50 large-scale biomarker discovery and validation studies for almost all therapeutic indications. Caprion is now present on four continents and has over 400 employees, mostly senior scientists.



View the capsules





Montréal InVivo would like to thank all the members of the Strategic Committee for their commitment

- **FRANK BÉRAUD** – Montréal InVivo
- **FRANÇOIS BERGERON** – MEDTEQ
- **FRANÇOIS BERGERON** – AccellAB Inc. **Co-Chair** (until June 2018) **Member of the Strategic Committee** (until July 2018)
- **CEDRIC BISSON** – Teralys Capital **Co-Chair** (since June 2018)
- **ÈVE BLANCHET** – Boehringer Ingelheim (since November 2018)
- **CLAUDE CHEVALIER** – **Co-Chair** (until May 2018)
- **MARTIN DOYON** – Ministry of Economy and Innovation, Government of Quebec (January 2018 to June 2018)
- **PIERRE FALARDEAU** – Bio-K Plus International Inc. **Co-Chair** (since January 2020)
- **YVON FRÉCHETTE** – Ministry of Economy and Innovation, Government of Quebec
- **INÈS HOLZBAUR** – AmorChem
- **MICHÈLE HOUPERT** – Ministry of Economy and Innovation, Government of Quebec (January to October 2018)
- **LILIANA KOROSI** – ROBIC (until July 2019)
- **FRÉDÉRIC LEDUC** – Immune Biosolutions
- **FRÉDÉRIC LEMAITRE-AUGER** – Accel-Rx
- **VANESSA MARSAN** – Ministry of Economy and Innovation, Government of Quebec (November 2018 to December 2019)
- **MICHAEL MEE** – Amplitude Ventures (since October 2019)
- **CAROLINE MÉNARD** – Innovation, Science and Economic Development Canada, Government of Canada
- **MAXIME RANGER** – AmorChem **Co-Chair** (July 2018 to December 2019)
- **FRANÇOIS RAVENELLE** – Inversago (since October 2019)
- **MICHEL ROUSSEAU** – Novartis Pharma Canada
- **CLAUDE VÉZEAU** – Katana Biopharma

Animation and coordination

- **MARIE-LISE DION** – Montréal InVivo


Skills and Talent Development

MANDATE

Supporting the next generation to promote retention of talent in the sector and develop the professionals' expertise to maintain and continuously improve training-employment adequacy.

The Greater Montréal area, with its universities, faculties of medicine, engineering schools, faculty of pharmacy and specialized technical programs can compete with many areas of the world in terms of the quantity and the quality of the LSHT training programs. To ensure that a talent pool is retained that meets industry needs, Montréal InVivo is working together with the Strategic Committee:

- Development of a training-employment-entrepreneurship adequacy study and a benchmarking of best practices in ongoing LSHT professional development
- Launch of the second cohort of the Life Sciences Entrepreneurship Development Program, a collaboration between Montréal InVivo, the Faculty of Pharmacy at Université de Montréal, and Concordia University's John Molson Executive Centre, IRICoR, District 3 and TransMedTech Institute
- Establishment of a LSHT career exploration pathway in collaboration with Montréal Relève





Achievements

Adequacy Study and Continuum Project

The study carried out in collaboration with Pharmabio Development, the Conseil emploi métropole (CEM) and the Ministry of Labour, Employment and Social Solidarity (MTESS), was published in fall 2019 and will be officially launched in 2020. At the same time, the work of the Work Group comprised of Montréal InVivo, Pharmabio Development, Université de Montréal, IVADO, Qualifications Québec and Collège Ahuntsic, continued to develop the Continuum Project which includes a continuing training program in bioinformatics, data science and artificial intelligence, as well as a practical bioinformatics community aiming to continuously improve the expertise and promotion of careers in data science.



Consult the study

“A good partnership is especially successful when two organizations, with different missions, unite their resources and their areas of expertise around the same issue. This year, one of the main priorities of the partnership that has brought us together for several years already, has undoubtedly to pool our influential leadership in order to establish common strategies to promote the different LSHT careers of the future, and increase the number of graduates in programs that will ensure succession in our industry’s key positions.”

KIM BOURGEOIS
Chief Executive Officer
Pharmabio Development



On Friday, October 25, 2019, Montréal InVivo invited several stakeholders from the life sciences and health technologies sector to come together and work on a project. We developed a video capsule in connection with a series of actions taken to support the diversity in the life sciences entrepreneurship community. This initiative is part of an agreement between Montréal InVivo and the “Accélérer l’entrepreneuriat” program of Ville de Montréal announced earlier. All together, these stakeholders represented the commitment of a sector in which gender equality and diversity go hand in hand with success and a thriving economy.

A second cohort for the Life Sciences Entrepreneurship Development Program

The Life Sciences Entrepreneurship Development Program (LSEDP), a practical and immersive training program created through a collaboration between Montréal InVivo, the Faculty of Pharmacy at Université de Montréal and Concordia University’s John Molson Executive Centre, launched its second cohort in February 2019, which included 19 participants. Montréal InVivo also developed an initiative to further support the development of the leadership of female entrepreneurs. Financed by the “Accélérer l’entrepreneuriat de la Ville de Montréal” program, Pfizer Canada, TransMedTech Institute and IRICoR, this project will support eight female entrepreneurs in the third cohort and for the 18 months following the end of the LSEDP. The participants benefit from enhancing programming with special access to key stakeholders from the sector thanks to the support of its committed sponsors (District 3, IRICoR, TransMedTech Institute, Pfizer Canada, the Oncopole, the Government of Quebec and Ville de Montréal).



Visit the Program’s website



View the Program’s promotional video



Focus on succession planning


Again this year, in collaboration with Pharmabio Development, 20 workshops were organized by the biopharmaceutical mobile unit to raise awareness in high school students in the Greater Montréal. We also worked together with Montréal Relève to hold a discovery circuit of careers in the life sciences and medical technology sector in which three groups of high school students had the opportunity to explore and understand the environment of public research organizations and private companies in the cluster during three weeks of tours.

In addition, we organized a LSHT express recruitment event in partnership with Montréal International, in order to enable university graduates seeking employment or internships to meet with companies from the cluster that have scientific and technical positions to fill.



Montréal InVivo would like to thank all the members of the Strategic Committee for their commitment

- **ÉRIC ATLAN** – Collège Ahuntsic
 - **BENOIT BARBEAU** – Université du Québec à Montréal, Faculty of Science
 - **FRANÇOIS BÉDARD** – Conseil emploi métropole
 - **EMILY BELL** – Research Institute - McGill University Health Centre
 - **MARIE-ÈVE BLANCHET-DESLOGES** – Montréal International
 - **MARTIAL BOIVIN** – Ordre des chimistes du Québec
 - **SYLVIE BOURDEAU** – Fasken
 - **KIM BOURGEOIS** – Pharmabio Development
 - **LUCIE BROUILLETTE** – Collège Ahuntsic
 - **VÉRONIQUE CHAMPAGNE** – Montréal Relève
 - **DENIS DEBLOIS** – Université de Montréal, Faculty of Pharmacy
 - **KARINE DESFOSSÉS** – Fasken
 - **PHILIPPE DESJARDINS** – Student
 - **MARIE-JOSÉE DIONNE** – École Polytechnique
 - **FRANÇOIS FABI** – Student
 - **CHARLOTTE FULCHIRON** – Montréal International
 - **VÉRONIQUE GERLAND** – Ville de Montréal, Service de développement économique
 - **DANY JENKINS** – Cégep Gérard-Godin
 - **NABIL KHALID** – Collège John Abbott
 - **VALÉRIE-MADELEINE LANCELOT** – John Molson Executive Centre
 - **MATHIEU LEFORT** – Montréal International
 - **JULIE MANTOVANI** – Institute for Research in Immunology and Cancer
 - **SANDRA NICHOL** – John Molson Executive Centre
 - **NATHALIE PARENT** – Université de Montréal, Faculty of Arts and Sciences
 - **MICHELLE SAVOIE** – Université de Montréal, Faculty of Pharmacy
 - **AUDREY SEGRET** – Institute for Research in Immunology and Cancer, Commercialization of Research
 - **JESSICA TRÉPANIÉ** – Pharmabio Development
- ### Animation and coordination
- **PATRICK D. PAQUETTE** – Montréal InVivo



Integration of innovations

MANDATE

Foster a cultural change to establish sustainable, multidisciplinary partnerships and drive the development of a culture of innovation. Propose or develop initiatives that integrate innovation, and that are intended to improve the efficiency of the health care network, the health of populations and economic growth.

A successful integration of innovations is central to an effective and innovative health care system. To achieve this, Montréal InVivo works together with the members of its Strategic Committee on three major initiatives:

- ∴ Consultation with health care professionals on the terms and conditions of integrating technological innovation in Quebec
- ∴ Development of a project to optimally deploy immuno-oncology innovations
- ∴ Process of ensuring access to health data



Achievements

Measure the value of real-world care innovations

In 2019, Montréal InVivo drafted a document synthesizing the consultations carried out by the Strategic Committee, on the health care network's ability to measure the value of industrial innovations in real care settings. A few recommendations were presented in the brief "Recommandations découlant des consultations sur les modalités d'intégration d'innovations technologiques dans le réseau de la santé au Québec" (Recommendations resulting from the consultations on the terms and conditions for integrating technological innovations into Quebec's health network), which was submitted as part of pre-budget consultations.

"Measuring the value of innovations in a real-life health care environment is a priority for the Strategic Committee. Our discussions improve the understanding of each other's specific issues. This is a key step in establishing lasting partnerships."

SOPHIE ROCHON
National Director – Health Policy and Patient Access
Novartis Oncology



Consult the brief



Access to health data

Montréal InVivo continues to closely follow the matter on access to health data, specifically, the development of activities facilitating access to health data for companies. The CITADEL project of the CRCHUM, supported by the National Table of Research Directors at the Quebec Ministry of Health and Social Services (MSSS), was presented to several strategic committees. In fall 2019, following consultations carried out in 2016 and 2017, Montréal InVivo organized two consultation sessions on companies' processes for accessing health data. Subsequently, the brief "Recommandations sur l'optimisation des processus d'accès aux données de santé en vue du budget provincial 2020-2021" (Recommendations on the optimization of processes for accessing health data for the 2020-2021 provincial budget), was submitted to the Office of the Ministry of Finance of Quebec.



Consult the brief

Better supporting the integration of immunotherapy in cancer

Remember that since 2018, the Strategic Committee has relied on a specialized working sub-group whose objective is to create new complementary tools to better support the deployment and implementation of immunotherapy in the treatment of cancer in Quebec and therefore promote communication between stakeholders active in research, the health care network and industry. In 2019, the working group met with several influential players. Discussions resulted in the project evolving towards the creation of an adapted tool for patients to participate in measuring the value of innovations in immunotherapy (patient-reported outcomes). At the initiative of this working group, those in charge of SARDO (clinical DB) and OPAL (online application allowing patients to contact their health care team) worked together to submit a common proposal in order to demonstrate the technical feasibility to connect SARDO and OPAL. This progress could allow the value of the innovations in a real-life health care environment to be measured and the side effects of immunotherapy to be effectively managed.



Montréal InVivo would like to thank all the members of the Strategic Committee for their commitment

- **DONALD ALLARD** – Bristol-Myers Squibb Canada
- **FRANK BÉRAUD** – Montréal InVivo
- **DANIEL BOUTHILLIER** – Kaneq Pharma
- **FABRICE BRUNET** – Centre Hospitalier de l'Université de Montréal – **Co-Chair**
- **SYLVAIN CHARBONNEAU** – Fonds de Recherche du Québec - Health
- **SYLVAIN CLERMONT** – Celgene
- **DENISE CLOUTIER** – Pfizer Canada
- **MICHÈLE DE GUISE** – Institut national d'excellence en santé et en services sociaux
- **ISABELLE GAGNON** – Roche Diagnostics
- **PAVEL HAMET** – Centre de Recherche du Centre Hospitalier de l'Université de Montréal
- **MARTIN HOULE** – Ministry of Economy, Science and Innovation, Government of Quebec
- **CAROLE JABET** – Centre de Recherche du Centre Hospitalier de l'Université de Montréal
- **JEAN LACHAINE** – Université de Montréal, Faculty of Pharmacy
- **PAUL L'ARCHEVÊQUE** – Bureau de l'innovation, Quebec Ministry of Health and Social Services
- **MÉLANIE LEBERRE** – **Student** Research Centre, Institut universitaire de gériatrie de Montréal
- **IRIS LEROUX** – MEDTEQ
- **FRANCE MIGNAULT** – Gilead
- **LUCIE OPATRNY** – Ministry of Health and Social Services
- **THIBAULT PERRETTI** – **Student** École des technologies supérieures
- **SOPHIE ROCHON** – Novartis Oncology **Co-Chair**


Animation and coordination

- **NATHALIE OUIMET** – Montréal InVivo



Members of the work committee on the integration of immunotherapy in cancer

- **DONALD ALLARD** – Bristol-Myers Squibb
- **CORINNE AUBRY** – Bureau de l'innovation, Quebec Ministry of Health and Social Services
- **GERALD BATIST** – Jewish General Hospital
- **VANESSA CLAVEAU** – Ministry of Economy and Innovation
- **SYLVAIN CLERMONT** – Celgene
- **DENISE CLOUTIER** – Pfizer Canada
- **MAXIME DUMAIS** – Oncopole
- **ISABELLE GAGNON** – Roche Diagnostic
- **JEAN LACHAINE** – Faculty of Pharmacy, Université de Montréal
- **STÉPHANIE LACROIX** – Merck Canada
- **JEAN-FRÉDÉRIC LAFONTAINE** – AstraZeneca
- **RÉJEAN LAPOINTE** – Centre de recherche du CHUM
- **PAUL L'ARCHEVÊQUE** – Bureau de l'innovation, Quebec Ministry of Health and Social Services
- **BRUCE MAZER** – Research Institute – McGill University Health Centre (RI-MUHC)
- **FRANCE MIGNAULT** – Gilead
- **LOUISE PAQUET** – Quebec Ministry of Health and Social Services
- **SOPHIE ROCHON** – Novartis oncologie
- **LOUISE ROUSSEAU** – Quebec Ministry of Health and Social Services
- **BERTRAND ROUTY** – Centre de recherche du CHUM




Issues Monitoring and Management

MANDATE

Play a sentinel, strategic and guiding role in identifying issues and trends affecting the industry and manage them as issues (research-investigation-strategies) while trying to cover the broadest possible spectrum of stakeholders from the cluster.

The members wondered about the direction to give to the Strategic Committee and agreed that they wished to retain responsibility for a certain degree of monitoring of public affairs and policies. It will also play a role in identifying issues and will need to ensure that they are dealt with by Montréal InVivo's different strategic committees. Where applicable, it may propose the creation of sub-committees as is the case for the Federal Positioning Table.



“Montréal InVivo continued to work with the other Canadian clusters and to intervene at the federal level to emphasize the importance of innovation and life sciences for Canadians. Many topics are addressed, but are focused around research funding, access to data, the value and the fair price to pay for its advances and the integration of innovations in the health care system. Continued advocacy is needed in favour of coherent federal public policies, in line with the provincial policies and promising for the future of the life sciences ecosystem.”

FRANÇOIS LAFLAMME
Director, Government Relations & Innovation
Eli Lilly Canada Inc.

Achievements

Provincial component

In 2019, the members of the Strategic Committee had expressed an interest in organizing an initiative to raise awareness among the elected officials. A working committee was therefore created to organize a day on Parliament Hill in February 2020. The firm Catapulte was commissioned to lead this initiative, which will inform the decision-makers of the challenges and issues in the LSHT sector.

Federal component


At the same time, the Federal Positioning Table, related to the Strategic Committee, focused on the analysis of the federal budget, the action plan for the federal campaign and the reform of the Patented Medicine Prices Review Board (PMPRB). A joint letter of support for the recommendations of the federal Health and Biosciences Strategic Table was also sent to the Minister of Finance shortly before the budget. Finally, a new letter addressing the issue of the PMPRB was drafted jointly with Life Sciences Ontario and sent to various federal ministers.



Consult the federal budget



Consult the provincial budget



Diversity and parity

A consultation table on diversity and parity in the LSHT sector was created in 2019 and worked on the objectives to achieve in terms of parity and on the development of an action plan. Other meetings are scheduled for 2020.

A big thank you to all members of the Strategic Committee for their commitment

Members of the Issues Monitoring and Management Strategic Committee

- **FRANK BÉRAUD** – Montréal InVivo
- **CHRISTIAN BERNARD** – Montréal International
- **SABRINA BERNIER** – Montréal InVivo
- **MICHEL BOUVIER** – Université de Montréal
- **VANESSA CLAVEAU** – Ministry of Economy and Innovation, Government of Quebec
- **PIERRE-ALEXANDRE FOURNIER** – Hexoskin
- **JULIE INSLEY** – Innovation, Science and Economic Development Canada, Government of Canada
- **FRANÇOIS LAFLAMME** – Eli Lilly Canada
- **DIDIER LECONTE** – Fonds de solidarité FTQ **Co-Chair**
- **IRÈNE MARCHETERRE** – Centre Hospitalier de l'Université de Montréal
- **MARC OSBORNE** – Roche Diagnostics **Co-Chair**
- **ANIE PERRAULT** – BioQuébec
- **SHANE RUSSELL** – Medtronic
- **ANTHONY T. CHUNG** – Engene Inc

Members of the Federal Positioning Table

- **NADÈGE ADAM** – MMM
- **FRÉDÉRIC ALBERRO** – IMC-MNC
- **SÉBASTIEN BEAUCHAMP** – Baxter
- **NADINE BEAUGER** – Université de Montréal
- **ANNE-SOPHIE BELZILE** – Innovative Medicines Canada
- **FRANÇOIS BERGERON** – AccelLAB
- **JOANNE CASTONGUAY** – Institut de recherche en politiques publiques
- **HÉLÈNE CHARTIER** – TELUS Health
- **FRANÇOIS DROLET** – Roche Diagnostics
- **DIANE GOSSELIN** – CQDM
- **JULIE INSLEY** – Innovation, Science and Economic Development Canada, Government of Canada
- **FRANÇOIS LAFLAMME** – Eli Lilly Canada **Table Manager**
- **GRAZIA MAION** – Gestion Univalor
- **CATHERINE VILLENEUVE** – Montréal InVivo

Animation and coordination

- **FRANK BÉRAUD** – Montréal InVivo



Research and Innovation

MANDATE

Enhance Greater Montréal's productivity and competitiveness in terms of research and development (R&D), in the talent race and promote the increase of public and private investments in R&D.

The Research and Innovation Strategic Committee supports and implements impactful projects that have a real impact on the sector and that also help to retain researchers:

- Strategic thinking for the identification of the attributes of a new structuring research and development project
- Identify strategic priorities improving Québec's competitiveness in order to develop diagnostic and therapeutic innovations for rare diseases
- Survey the medical Cannabis industrial players to better understand the environment and opportunities
- Develop a fourth page of "niche of excellence" on artificial intelligence applied to life sciences and health technologies



“To optimize the positioning of the initiative on rare diseases, and through means of communication, we have had discussions with international industrial leaders. This forward-looking approach is stimulating for the Strategic Committee and allows us to seek ideas from everywhere.”

VRATISLAV HADRAVA
Vice-President and Medical Director
Pfizer Canada

Achievements

Public-private mobilization project

The Strategic Committee carried out a strategic discussion in 2019 to identify the attributes of a new impactful project to improve Greater Montréal’s competitiveness in R&D. This discussion led to the following results:

- Created a complete research ecosystem
- Built on transdisciplinarity in research
- Looked to the R&D needs of the future
- Included information technology components in health and artificial intelligence
- Provided data access and sharing and centralized research databases
- Stimulated public-private partnerships and stimulated the creation of jobs of Quebec SMEs



Rare diseases

Building on the strategic thinking presented at the last page, and on the fact that the MSSS is also developing a strategy on rare diseases to optimize its provision of care, the Strategic Committee prioritized the deployment of the rare diseases niche. Several rare disease specialists from various sectors met with members of the Strategic Committee to validate their strategic analysis. The priorities identified in 2019 will be presented to a group of public and private research experts beginning in 2020. The purpose is to improve competitiveness in industrial research to develop diagnostic and therapeutic innovations for rare diseases. To achieve this objective, the following areas of development were prioritized:

- Quebec expertise is dispersed; it is therefore better to know the most distinctive sub-niches of expertise and promote collaboration
- Combining diagnostic data creates a distinctive asset to attract investments and stimulate companies to work on this sector
- R&D process innovation is needed to lower costs and therefore encourage investment in this sector
- Several types of stakeholders need to collaborate to improve access to diagnostics and innovative treatments in Quebec



The medical cannabis industry

Since the legalization of recreational cannabis, the focus on the Quebec industry has continued to grow. Montréal InVivo met with a number of leaders to gain a deeper understanding of the environment and the opportunities. These preliminary discussions have demonstrated the sector's interest in medical cannabis. Given Montréal InVivo's expertise in the initiation of new collective projects, we created a working group on this sector, specifically on cannabis products with a therapeutic effect. An action plan will be implemented in 2020.

Niches of excellence

For two years, Montréal InVivo has been developing web pages illustrating the successes of different niches of excellence in order to support the attractiveness of the life sciences and health technologies ecosystem. The visibility of these niches strengthens the connections between industry, research and funding. This year, Montréal InVivo created a new page on the artificial intelligence niche on the basis of its positioning study in life sciences.



Consult the AI niche page



Montréal InVivo would like to thank all the members of the Strategic Committee for their commitment

- **CARL-ÉRIC AUBIN** – TransMedTech and École Polytechnique
- **CHRISTIAN BARON** – Université de Montréal
- **NADINE BEAUGER** – Institute for Research in Immunology and Cancer, Commercialization of Research
- **FRANK BÉRAUD** – Montréal InVivo
- **MARCO BLOUIN** – Ministry of Economy, Science and Innovation, Government of Quebec
- **MARIO CHEVRETTE** – Consortium québécois sur la découverte du médicament
- **JACQUES DE GUISE** – École des Technologies supérieures and Centre Hospitalier de l'Université de Montréal
- **VRATISLAV HADRAVA** – Pfizer Canada **Co-Chair**
- **DANIKA LABERGE** – CATALIS Québec
- **MONIQUE LACROIX** – Novartis Pharma
- **STÉPHANIE LORD-FONTAINE** – Oncopole
- **GRAZIA MAION** – Univalor
- **SERGE MARCHAND** – Fonds de Recherche du Québec en santé **Co-Chair**
- **NOLWENN NOISEL** – CARTaGENE
- **VIVIANE POUPON** – Montréal Neurological Institute
- **MANON ST-PIERRE** – Ministry of Health and Social Services
- **LAURENT TILLEMENT** – Servier Canada

Animation and coordination

- **NATHALIE OUIMET** – Montréal InVivo



Artificial Intelligence

MANDATE

Foster the development of the sector through the growth of organizations specialized in artificial intelligence (AI) applied to health and the increased use of AI in more traditional companies in the LSHT sector, in the various stages of the innovation cycle, from diagnosis to therapy, and for health prevention and management of care administration.

To achieve this goal, the following objectives have been prioritized:

- Define a development strategy differentiated from the sector
- Facilitate concerted collaboration between the stakeholders (development and adoption of AI in LSHT)
- Ensure a financing chain that is complete and adapted to AI in LSHT



“Discovery, diagnostics, clinical research, supply chain management: there are many applications of artificial intelligence (AI) in the LSHT sector and AI is already positioned as a critical tool to improve efficiency, precision and quality. The Strategic Committee brings together many areas of expertise in line with AI and LSHT from different disciplines; this interdisciplinarity encouraged by Montréal InVivo is a key factor in the success of the Strategic Committee in its mission.”

RANYA EL-MASRI
Head of Government Affairs and Market Access
GlaxoSmithKline

Achievements

The Strategic Committee monitored the development and validated the results of the study on artificial intelligence in Quebec’s life sciences and health technologies sector. This study listed the companies active in this sector including 55 startups, of which 24% are developing medical decision support diagnosis. Among the more traditional companies in the life sciences sector, 40% of them mentioned that they were developing or using AI. It is the companies from the medical technologies sector that develop or use AI the most with 47%. For this study, consultants conducted a series of interviews with stakeholders from the community to identify the main assets and issues and propose seven impactful solutions that would make the sector more competitive.



Consult the study



Montréal InVivo would like to thank all the members of the Strategic Committee for their commitment

- **ALEXANDRE LE BOUTHILLIER** – Imagia **Co-Chair**
- **RANYA EL-MASRI** – GlaxoSmithKline **Co-Chair**
- **NADINE BEAUGER** – Institute for Research in Immunology and Cancer, Commercialization of Research
- **FRANK BÉRAUD** – Montréal InVivo
- **DAVID BERTRAND** – TechnoMontréal
- **VANESSA CLAVEAU** – Ministry of Economy and Innovation, Government of Quebec
- **FRANCOIS DROLET** – Roche Diagnostics
- **CHRISTELLE FASANO** – Montréal International
- **LÉA BERLINGUET** – Montréal International
- **PIERRE ALEXANDRE FOURNIER** – Hexoskin
- **CAROLE JABET** – Fonds de recherche du Québec
- **SARAH JENNA** – MyIntelligentMachines (MIMs)
- **MERYEME LAHMAMI** – MEDTEQ
- **PAUL L'ARCHEVÊQUE** – Bureau de l'innovation, Quebec Ministry of Health and Social Services
- **BENOIT LAROSE** – MEDEC
- **MARTIN LEBLANC** – Caprion
- **STÉPHANE LÉTOURNEAU** – MILA
- **ERIKA-ESTHER LUAMBA** – Ministry of Economy and Innovation, Government of Quebec
- **KATHY MALAS** – Centre Hospitalier de l'Université de Montréal
- **CAROLINE MÉNARD** – Innovation, Science and Economic Development Canada, Government of Canada
- **SAMIR MOUNIR** – Desjardins
- **NOLWENN NOISEL** – CARTaGENE
- **DOINA PRECUP** – Healthy Brains for Healthy Lives, McGill University
- **MAXIME RANGER** – AmorChem
- **JEAN-PIERRE ROBERT** – CTS Santé
- **LOUIS ROY** – IBM Corporation
- **SHANE RUSSELL** – Medtronic Canada
- **LUC SIROIS** – PROMPT
- **ISABELLE VÉZINA** – Hacking Health
- **LUC VILANDRÉ** – TELUS Santé

Animation and coordination

- **MARIE-LISE DION** – Montréal InVivo



Outreach

Our communications colleagues are working hard to create exclusive content and relay important information to the members of the sector through many newsletters that highlight the sector's successes and promote the Cluster's Canada-wide outreach.



Subscribe to our newsletters


WE ARE

At the heart of the ecosystem of Life Sciences and Health Technologies of Greater Montréal

A new website and a new visual identity

Montréal InVivo is striving to offer value-added content in order to be the reference for the sector. Montréal InVivo's website is the platform in which players from industry, research, influencers and public decision-makers support each other to stay current regarding the sector.

This is why the website was completely revamped in 2019. It was entirely reworked to make the user's experience more enjoyable and facilitate information searches. In addition, our organization's visual identity was reviewed to strengthen Montréal InVivo's profile.



The logo was slightly modernized to maintain the profile of acquired over the years. The placement of the bubbles was redesigned to represent the collaborative work of Montréal InVivo and the Cluster of the Life Sciences and Health Technologies sector.

Montréal InVivo and its CEO are increasingly recognized as a reference for journalists.



Some of the interviews conducted in 2019 are as follows:



JANUARY 15, 2019

Media interview with C l'hebdo
Biotechnologies and life sciences



FEBRUARY 5, 2019

Media interview with Media Planet
Investing in life sciences



FEBRUARY 8, 2019

Media interview with Véronique Champagne
Artificial intelligence in the pharmaceutical sector




FEBRUARY 25, 2019

Interview with the newspaper La Presse
Clinical research



45 newsletters

(INFOINVIVO, RESOINVIVO and FLASHINVIVO) with 3,643 subscribers



79 events

published on the calendar



59,495 visits

on the pages of our website



Social media FOLLOWERS

+7% ↑ 1,830 · Twitter

+8% ↑ 7,545 · LinkedIn

+25% ↑ 265 · Facebook



Mobilization

Throughout the year, the members of the Montréal InVivo team have initiated, participated in or organized a large number of events and meetings to maintain lasting relationships with the various members of the sector and strengthen its positioning.



The CEO also spent many hours developing new relationships, whether with potential partners, with economic or political influencers, with the business world outside the LSHT sector, or even when hosting foreign companies or delegations from the United States, France, Belgium, India or Sweden.

Milestones

Effervescence 2019: a successful first edition

Initiated in 2018 by Montréal InVivo, EFFERVESCENCE – the future of life sciences, was co-created with 14 partners from the life sciences and health technologies sector. The first edition of the event brought together 550 participants, including 116 speakers, to present nine 90-minute sessions addressing various topics and a short breakfast conference, eight flash presentations to present specific local assets, four 60-minute training sessions for a total of 1,290 hours of inspiring content! The second edition was to take place on April 22 and 23, 2020, but was postponed due to the COVID-19 pandemic.



Consult the event

Events under the leadership of Montréal InVivo



779 Participants



30.9 Duration (h)



Some events organized by our partners in which the Montréal InVivo team participated

JANUARY 14

**MEDTEQ
Innovation Summit**

JANUARY 30

**AI For Health -
January Meetup**

FEBRUARY 18

**Artificial Intelligence
Forum**

FEBRUARY 28

**Quebec Cancer
Coalition event**

MARCH 20

**GQ event -
Ready for Genomics?**

MARCH 27

**Working Committee
Grappes - Je choisis
Montréal**

APRIL 4

Centech DEMO day

APRIL 4

**Awards Ceremony -
McGill Dobson Cup
2019 powered
by National Bank**

APRIL 23

Sweet Pharma Day

MAY 14

BBMESS Symposium

JUNE 18

**Conference for
patient and caregiver
associations**

JULY 25

Demo Day by Centech

AUGUST 22

**Launch of the
Pôle montréalais
d'enseignement
supérieur en IA**

SEPTEMBER 16

**TVM Capital Life
Science - Autumn
Conference 2019**

SEPTEMBER 17

**AI Forum –
Italy - Canada**

SEPTEMBER 20

**Première ligne
en santé**

SEPTEMBER 23 - 25

**The Medtech
Conference**

OCTOBER 30

**Les Entretiens Janssen
Edition 2019**

NOVEMBER 26

**BioTalent Canada -
LMI Roundtable -
IMT Table ronde**

NOVEMBER 27

**Conférence Éthique
de l'IA**



Decision- makers

We have the opportunity to benefit from the support and smart advice of several leaders who help us develop promising projects for the entire sector. Their input is essential for Montréal InVivo and we would like to take the opportunity to sincerely thank them for their commitment.

Members of the Board of Directors

- **FRANK BÉRAUD*** – **Chief Executive Officer** Montréal InVivo
- **CÉDRIC BISSON*** – Teralys Capital
- **FABRICE BRUNET** – Centre Hospitalier de l'Université de Montréal
- **FRÉDÉRIC FASANO** – Servier Canada
- **DIANE GOSSSELIN*** – Consortium québécois sur la découverte du médicament
- **WHITNEY GREEN** – Roche Diagnostics (until April 12, 2019)
- **PHILIPPE GROS** – McGill University
- **PAVEL HAMET** – Medpharmgene
- **MARIE-JOSÉE HÉBERT** – Université de Montréal
- **YOO-SEOK HONG** – GlaxoSmithKline Pharma Inc.
- **PATRICK HUPÉ** – Medtronic Canada
- **ALEXANDRE LE BOUTHILLIER** – Imagia
- **DIDIER LECONTE** – Fonds de solidarité FTQ (until November 19, 2019)
- **BRUCE MAZER** – Research Institute – McGill University Health Centre (RI-MUHC)
- **JACQUES MILETTE** – MEDTEQ
- **JEAN-MAURICE PLOURDE** – **Honorary Member** Montréal InVivo
- **RÉMI QUIRION** – Fonds de recherche du Québec (FRQ)
- **SUZY TALBOT** – DIEX Recherche (since October 2018)
- **ANNA VAN ACKER** – Merck Canada Inc.
- **LUC VILANDRÉ** – TELUS Health (since December 2018)

Chairman of the Board

- **MARTIN LEBLANC*** – Caprion Biosciences Inc.

Vice-Chairman of the Board

- **JACQUES GAGNÉ*** – **Honorary Member** Montréal InVivo

Secretary-Treasurer of the Board

- **PIERRE FALARDEAU*** – Bio-K Plus International Inc.

* Members of the Executive Committee



Our allies

The financial support from our partners enables us to conduct major projects and create new unifying initiatives. Their support strengthens the credibility of our work and we would like to take this opportunity to thank them for their trust. We can also rely on the collaboration of many other stakeholders in the sector that allow us to go further in our activities.

Financial partners

- [AbbVie](#)
- [Accel-Rx](#)
- [Accreon](#)
- [Altasciences](#)
- [AstraZeneca](#)
- [Bausch Health \(Valeant\)](#)
- [Baxter Corporation](#)
- [Biogen Canada Inc.](#)
- [BioQuébec](#)
- [Bristol-Myers Squibb](#)
- [Boehringer Ingelheim Canada Ltd.](#)
- [Caisse Desjardins du Réseau de la Santé](#)
- [Caprion Biosciences](#)
- [Celgene](#)
- [Cirion BioPharma Recherche Inc.](#)
- [Cité de la Biotech](#)
- [Citoyen Optimum](#)
- [CIUSSS du Centre-Sud-de-l'Île-de-Montréal](#)
- [Concordia University](#)
- [Consortium MEDTEQ](#)
- [Consortium québécois sur la découverte du médicament \(CQDM\)](#)
- [CTS Santé](#)
- [Eli Lilly Canada](#)
- [Entreprises Amorchem](#)
- [Exka Inc.](#)
- [FASKEN](#)
- [Fonds de recherche du Québec - Santé \(FRQS\)](#)
- [Fonds de solidarité FTQ](#)
- [Génomique Québec](#)
- [Gestion Univalor](#)
- [Gilead Sciences Canada](#)
- [GlaxoSmithKline Inc.](#)
- [Hermes Medical Solutions Canada Inc.](#)
- [Imagia](#)
- [Janssen Inc.](#)
- [McGill University](#)
- [Medpharmgene](#)
- [Medtronic Canada](#)
- [Merck Canada](#)
- [National Bank](#)
- [National Research Council Canada \(NRCC\) – Human Health Therapeutics](#)
- [NÉOMED](#)
- [NÉOMED LABS](#)
- [Novartis Pharma Canada](#)
- [Novo Nordisk Canada Inc.](#)
- [Oncopole](#)
- [Pfizer Canada](#)
- [Plakett Service Clinique](#)
- [Research Institute of the McGill University Health Centre](#)
- [Réseau universitaire intégré de santé et de services sociaux de l'Université de Montréal \(RUISSS de l'UdeM\)](#)
- [Roche Diagnostics](#)
- [Saint-Hyacinthe Technopole](#)
- [Sanofi Canada](#)
- [Sectoral asset Management Inc.](#)
- [Servier Canada](#)

- [TELUS Health](#)
- [Teralys Capital](#)
- [Teva Canada Innovation](#)
- [TransBIOTech](#)
- [Université de Montréal](#)
- [Vertex Pharmaceuticals \(Canada\)](#)

Government of Quebec

- [Ministry of Economy and Innovation \(MEI\)](#)
- [Secrétariat à la région métropolitaine](#)

Government of Canada

- [Canada Economic Development of Quebec Regions](#)
- [ICCI Program; Can Export Canada for Quebec Regions](#)

Municipal

- [Communauté Métropolitaine de Montréal \(CMM\)](#)
- [Ville de Montréal](#)

Partnership Agreements

- [Life Sciences Ontario \(LSO\)](#)
- [Innovative Medicines Canada](#)

Contributors

- [Aéro Montréal](#)
- [Aligo Innovation](#)
- [AluQuébec](#)
- [Bureau du cinéma et de la télévision du Québec](#)
- [Cargo M](#)
- [Cartagene](#)

- [CATALIS Québec](#)
- [CÉGEP Gérald-Godin](#)
- [Chamber of Commerce of Metropolitan Montréal \(CCMM\)](#)
- [CHU Sainte-Justine](#)
- [CIUSSS de la Capitale-Nationale](#)
- [CIUSSS de la Mauricie-et-du-Centre-du-Québec](#)
- [CIUSSS Estrie](#)
- [Clinical Trials Ontario](#)
- [Collège Ahuntsic](#)
- [John-Abbott College](#)
- [Centre de recherche du CHUM \(CRCHUM\)](#)
- [District 3 Innovation Center](#)
- [Écotech Québec](#)
- [Emploi-Québec](#)
- [Essais Cliniques Simplifiés](#)
- [Finance Montréal](#)
- [Fondation de l'entrepreneurship - Réseau M](#)
- [Hacking Health](#)
- [Hexoskin](#)
- [INESSS](#)
- [Innovation, Science et Economic Development Canada](#)
- [Institut de recherches cliniques de Montréal \(IRCM\)](#)
- [Investissement Québec](#)
- [IRIC](#)
- [IRICoR](#)
- [IVADO](#)
- [John Molson School of Business](#)
- [Lavery](#)

- [MEDEC](#)
- [Mila](#)
- [My Intelligent Machines \(MIMs\)](#)
- [Ministère de la Santé et des Services sociaux du Québec](#)
- [mmode](#)
- [Montréal International](#)
- [Montréal Relève](#)
- [Ordre des chimistes du Québec](#)
- [Palais des congrès de Montréal](#)
- [Pharmabio Développement](#)
- [Polytechnique Montréal](#)
- [Prompt](#)
- [Propulsion Québec](#)
- [Qualification Québec](#)
- [Québec International](#)
- [Quebec Network for Personalized Health Care \(QNPHC\)](#)
- [Québec Vitae](#)
- [Royal Bank of Canada](#)
- [Services Québec](#)
- [Sherbrooke Innopole](#)
- [SOVAR](#)
- [TechnoMontréal](#)
- [TOHealth!](#)
- [TransMedTech Institute](#)
- [Université du Québec à Montréal \(UQAM\)](#)

Consult the web links

A photograph of three women in a meeting. One woman is standing and pointing at a document on a table, while two others are seated and looking at the document. The scene is set in an office with an 'EXIT' sign visible in the background. The image is partially covered by a large orange semi-circle.

Our team

Passionate and collaborative, all the members of our team are motivated to work together with all stakeholders in the sector. We share the same vision: mobilize and work together on common goals to strengthen the growth and competitiveness of the LSHT sector.



We are pleased to welcome back Sabrina Bernier and welcome Farah Bendahmane and Baha Eddin Dakhli to our team for 2020.

We would like to take the opportunity to thank Marie-Lise Dion, Patrick D. Paquette and Catherine Villeneuve for their contribution to Montréal InVivo's project development. Their leadership and dedication contributed to the emergence of new strategic committees and new initiatives that will benefit the entire sector.

- **FRANK BÉRAUD**
Chief Executive Officer
- **NATALIE OUIMET**
Vice-President, Operations
- **MARIE-LISE DION**
Director – Business and Strategic Initiatives
(until November)
- **PATRICK D. PAQUETTE**
Associate Director – Skills and Talent
Development (until November)
- **CATHERINE VILLENEUVE**
Project Manager, Communications (until July)
- **DIANE HUBERT**
Executive Assistant and Corporate Affairs
Coordinator
- **CLAUDIE NOËL**
Director – Skills and Talent Development
(December)
- **VÉRONIQUE ROCHEFORT**
Coordinator – Communications

Stakeholders' presence



The participation of stakeholders in our activities is essential. It allows us to better understand the needs of the sector and undertake initiatives that foster discussions, the creation of partnerships and “co-creation.” We would like to take this opportunity to thank all the stakeholders for their ongoing presence.

Table

OF PARTICIPATION OF STAKEHOLDERS IN THE CLUSTER

2019

TYPE AND DATE OF THE 2019 MEETINGS

	DURATION (H)	NUMBER OF PARTICIPANTS	NUMBER OF PRIVATE PARTICIPANTS	TOTAL PARTICIPANT CONTRIBUTION (H)	AVERAGE HOURLY RATE	INDUSTRIAL IN-KIND CONTRIBUTION	PUBLIC/SEMI- PUBLIC IN-KIND CONTRIBUTION	GRAND TOTAL IN-KIND CONTRIBUTION
Annual General meeting	1.5	91	42	136.5	\$200	\$12,600	\$14,700	\$27,300
Board of Directors	10	68	24	175	\$200	\$12,000	\$22,000	\$34,000
Executive Committee	6,5	16	10	26	\$200	\$3,500	\$2,000	\$5,500
Governance Committee	4.75	12	4	15	\$200	\$1,250	\$2,550	\$3,800
Finance Committee	2.5	5	5	6	\$200	\$1,200	\$0	\$1,200
Strategic Committee – Growth of Companies	7.5	49	38	86	\$200	\$13,400	\$3,800	\$17,200
BIOSUCCÈS Mentoring Network	21.5	62	43	132.5	\$200	\$19,100	\$7,400	\$26,500
Life Sciences Entrepreneurship Development Program	5	73	26	135.5	\$200	\$8,500	\$15,300	\$23,800
Strategic Committee – Integration of Innovations	4	32	14	64	\$200	\$2,800	\$4,000	\$6,800
Immuno-oncology Working Group	5.5	43	18	81.5	\$200	\$6,900	\$9,400	\$16,300
Strategic Committee – Research and Innovation	8	65	26	130	\$200	\$8,400	\$12,400	\$20,800
Working Groups – Health data access process	4	24	10	48	\$200	\$4,000	\$5,600	\$9,600
Strategic Committee – Issues Monitoring and Management	6	21	8	42	\$200	\$3,200	\$5,200	\$8,400

Table

OF PARTICIPATION OF STAKEHOLDERS IN THE CLUSTER

2019


TYPE AND DATE OF THE 2019 MEETINGS

	DURATION (H)	NUMBER OF PARTICIPANTS	NUMBER OF PRIVATE PARTICIPANTS	TOTAL PARTICIPANT CONTRIBUTION (H)	AVERAGE HOURLY RATE	INDUSTRIAL IN-KIND CONTRIBUTION	PUBLIC/SEMI- PUBLIC IN-KIND CONTRIBUTION	GRAND TOTAL IN-KIND CONTRIBUTION
Table: Federal Positioning	3.5	17	8	29.5	\$200	\$2,800	\$3,100	\$5,900
Table: Creation of a Medtech fund	1.5	6	1	9	\$200	\$300	\$1,500	\$1,800
Table: LSHT Awareness	2	4	1	8	\$200	\$400	\$1,200	\$1,600
Committee: Activity on the Hill (Provincial)	5.45	35	6	50.15	\$200	\$2,000	\$8,030	\$10,030
Committee: Parity and diversity	5.5	34	17	50	\$200	\$5,100	\$4,900	\$10,000
Strategic Committee – Artificial Intelligence	7.5	59	26	112	\$200	\$9,900	\$12,500	\$22,400
LSHT Artificial Intelligence Committee	12.95	62	37	133.35	\$200	\$15,470	\$11,200	\$26,670
Strategic Committee – Skills and Talent Development	8	36	2	74	\$200	\$1,000	\$13,800	\$14,800
Continuum Project	8.5	38	10	111	\$200	\$8,000	\$14,200	\$22,200
Pilot Committee: Adequacy diagnosis	3	21	3	38	\$200	\$1,000	\$6,600	\$7,600
EFFERVESCENT Organization	35	226	69	415	\$200	\$35,100	\$74,900	\$110,000
Sub-TOTAL	179.65	1,099	448	2,108	\$200	\$177,920	\$256,280	\$434,200

Total

PARTICIPATION
OF STAKEHOLDERS IN THE CLUSTER

NUMBER OF PARTICIPANTS



Number of participants



Number of private participants

\$ CONTRIBUTION

\$177,920
Industrial In-Kind
contribution

\$256,280
Public/semi-public
In-Kind contribution

\$434,200
Grand total
In-kind
contribution



179 hours



1,856 participants



448 private
participants



2,108 hours
of participation

630 Sherbrooke Street West Suite 460
Montréal, Quebec H3A 1E4

514 987-9377
montreal-invivo.com



MONTRÉAL
INVIVO 